Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19
Abstract Background The worldwide pandemic of COVID-19 remains a serious public health menace as the lack of efficacious treatments. Cytokine storm syndrome (CSS) characterized with elevated inflammation and multi-organs failure is closely correlated with the bad outcome of COVID-19. Hence, inhibit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-06-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-021-00926-0 |
| _version_ | 1818474245820252160 |
|---|---|
| author | Qingqin Tan Lingjie He Xiaojun Meng Wei Wang Hudan Pan Weiguo Yin Tianchuan Zhu Xi Huang Hong Shan |
| author_facet | Qingqin Tan Lingjie He Xiaojun Meng Wei Wang Hudan Pan Weiguo Yin Tianchuan Zhu Xi Huang Hong Shan |
| author_sort | Qingqin Tan |
| collection | DOAJ |
| description | Abstract Background The worldwide pandemic of COVID-19 remains a serious public health menace as the lack of efficacious treatments. Cytokine storm syndrome (CSS) characterized with elevated inflammation and multi-organs failure is closely correlated with the bad outcome of COVID-19. Hence, inhibit the process of CSS by controlling excessive inflammation is considered one of the most promising ways for COVID-19 treatment. Results Here, we developed a biomimetic nanocarrier based drug delivery system against COVID-19 via anti-inflammation and antiviral treatment simultaneously. Firstly, lopinavir (LPV) as model antiviral drug was loaded in the polymeric nanoparticles (PLGA-LPV NPs). Afterwards, macrophage membranes were coated on the PLGA-LPV NPs to constitute drugs loaded macrophage biomimetic nanocarriers (PLGA-LPV@M). In the study, PLGA-LPV@M could neutralize multiple proinflammatory cytokines and effectively suppress the activation of macrophages and neutrophils. Furthermore, the formation of NETs induced by COVID-19 patients serum could be reduced by PLGA-LPV@M as well. In a mouse model of coronavirus infection, PLGA-LPV@M exhibited significant targeted ability to inflammation sites, and superior therapeutic efficacy in inflammation alleviation and tissues viral loads reduction. Conclusion Collectively, such macrophage biomimetic nanocarriers based drug delivery system showed favorable anti-inflammation and targeted antiviral effects, which may possess a comprehensive therapeutic value in COVID-19 treatment. |
| first_indexed | 2024-04-14T04:34:23Z |
| format | Article |
| id | doaj.art-da7bc65400464e0490930aa4945b4e17 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-14T04:34:23Z |
| publishDate | 2021-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-da7bc65400464e0490930aa4945b4e172022-12-22T02:11:56ZengBMCJournal of Nanobiotechnology1477-31552021-06-0119111610.1186/s12951-021-00926-0Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19Qingqin Tan0Lingjie He1Xiaojun Meng2Wei Wang3Hudan Pan4Weiguo Yin5Tianchuan Zhu6Xi Huang7Hong Shan8Center for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityCenter for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Endocrinology, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityCenter for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityDr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and TechnologyThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s HospitalCenter for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityCenter for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityCenter for Infection and Immunity, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital of Sun Yat-Sen UniversityAbstract Background The worldwide pandemic of COVID-19 remains a serious public health menace as the lack of efficacious treatments. Cytokine storm syndrome (CSS) characterized with elevated inflammation and multi-organs failure is closely correlated with the bad outcome of COVID-19. Hence, inhibit the process of CSS by controlling excessive inflammation is considered one of the most promising ways for COVID-19 treatment. Results Here, we developed a biomimetic nanocarrier based drug delivery system against COVID-19 via anti-inflammation and antiviral treatment simultaneously. Firstly, lopinavir (LPV) as model antiviral drug was loaded in the polymeric nanoparticles (PLGA-LPV NPs). Afterwards, macrophage membranes were coated on the PLGA-LPV NPs to constitute drugs loaded macrophage biomimetic nanocarriers (PLGA-LPV@M). In the study, PLGA-LPV@M could neutralize multiple proinflammatory cytokines and effectively suppress the activation of macrophages and neutrophils. Furthermore, the formation of NETs induced by COVID-19 patients serum could be reduced by PLGA-LPV@M as well. In a mouse model of coronavirus infection, PLGA-LPV@M exhibited significant targeted ability to inflammation sites, and superior therapeutic efficacy in inflammation alleviation and tissues viral loads reduction. Conclusion Collectively, such macrophage biomimetic nanocarriers based drug delivery system showed favorable anti-inflammation and targeted antiviral effects, which may possess a comprehensive therapeutic value in COVID-19 treatment.https://doi.org/10.1186/s12951-021-00926-0COVID-19Cytokine storm syndromeAnti-inflammationAntiviral treatmentBiomimetic nanocarriers |
| spellingShingle | Qingqin Tan Lingjie He Xiaojun Meng Wei Wang Hudan Pan Weiguo Yin Tianchuan Zhu Xi Huang Hong Shan Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19 Journal of Nanobiotechnology COVID-19 Cytokine storm syndrome Anti-inflammation Antiviral treatment Biomimetic nanocarriers |
| title | Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19 |
| title_full | Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19 |
| title_fullStr | Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19 |
| title_full_unstemmed | Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19 |
| title_short | Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19 |
| title_sort | macrophage biomimetic nanocarriers for anti inflammation and targeted antiviral treatment in covid 19 |
| topic | COVID-19 Cytokine storm syndrome Anti-inflammation Antiviral treatment Biomimetic nanocarriers |
| url | https://doi.org/10.1186/s12951-021-00926-0 |
| work_keys_str_mv | AT qingqintan macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT lingjiehe macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT xiaojunmeng macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT weiwang macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT hudanpan macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT weiguoyin macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT tianchuanzhu macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT xihuang macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 AT hongshan macrophagebiomimeticnanocarriersforantiinflammationandtargetedantiviraltreatmentincovid19 |